Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S461000, C546S281700, C546S276400, C546S280400, C549S429000
Reexamination Certificate
active
10721525
ABSTRACT:
A compound of Formula (I):wherein:X is selected from the group consisting of O, S, and NR17, where R17is hydrogen or lower alkyl;A and Y are CH, N, NR17, O, or S;C1and C2are each C or N, wherein C1and C2are the same or different;D1and D2are each C or N, wherein D1and D2are the same or different;B and Z are CH, N, or NR17, provided that B, Z, or both B and Z are not present when A, Y, or both A and Y are O, S, or NR17;R13, R14, R1and R8can be present or absent, and when present are selected from the group consisting of H, lower alkyl, halogen, alkoxyl, aryloxyl, aralkoxy and hydroxyl;R15and Rare selected from the group consisting of H, lower alkyl, halogen, alkoxyl, aryloxyl, aralkoxy and hydroxyl;R3and R6are each independently selected from the group consisting of H, hydroxy, lower alkyl, cycloalkyl, aryl, aralkyl, alkoxyl, hydroxycycloalkyl, alkoxycycloalkyl, hydroxyalkyl, aminoalkyl, acyloxy, acetoxy, and alkylaminoalkyl; and R2, R4, R5and R7are each independently selected from the group consisting of H, lower alkyl, alkoxyalkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, and alkylaminoalkyl, or R2and R4together or R5and R7together represent a C2to C10alkyl, hydroxyalkyl, or alkylene, or R3and R4together or R6and R7together are:wherein n is a number from 1 to 3, and R9is H or —CONHR10NR11R12, wherein R10is lower alkyl and R11and R12are each independently selected from the group consisting of H and lower alkyl.
REFERENCES:
patent: 6706754 (2004-03-01), Werbovetz et al.
patent: WO 00/04893 (2000-02-01), None
patent: WO 01/03685 (2001-01-01), None
patent: WO02/36588 (2002-05-01), None
Ismail, M. A. et al., “Synthesis and Antiprotozoal Activity of Aza-Analogues of Furamidine”,Journal of Medicinal Chemistry, vol. 46, No. 22, pp. 4761-4769, 2003.
Trent, J. O. et al., Targeting the Minor Groove of DNA: Crystal Structures of Two Complexes Between Furan Derivatives of Berenil and the DNA Dodecamer d(CGCGAATTCGCG)2,Journal of Medicinal Chemistry, vol. 39, No. 23, pp. 4554-4562, 1996.
International Preliminary Examination Report corresponding PCT Appl. No. PCT/US03/37691 dated Jul. 6, 2004.
Bell et al.,Structure-Activity Relationships of Analogs of Pentamidine Against Plasmodium falciparum and Leishmania mexicana amazonensis, Antimicrobial Agents and Chemotherapy34(7):1381-1386 (Jul. 1990).
Bell et al.,Structure-Activity Relationships of Pentamidine Analogs against Giardia lamblia and Correlation of Antigiardial Activity with DNA-Binding Affinity, Antimicrobial Agents and Chemotherapy35(6):1099-1107 (Jun. 1991).
Blagburn et al.,Inhibition of Cryptosporidium parvum in Neonatal Hsd:(ICR)BR Swiss Mice by Polyether Ionophores and Aromatic Amidines, Antimicrobial Agents and Chemotherapy35(7):1520-1523 (Jul. 1991).
Boykin et al.,Dicationic Diarylfurans and Anti-pneumocystis carinii Agents, J. Med. Chem. 38:912-916 (1995).
Boykin et al.,2,5-Bis[4-(N-alkylamidino)phenyl]furans as Anti-pneumocystis carinii Agents, J. Med. Chem. 41:124-129 (1998).
Das et al.,Synthesis and Antiprotozoal Activity of 2,5-Bis(4-guanylphenyl)furans, J. of Med. Chem. 20(4):531-536 (1977).
Del Poeta et al.,Structure-in Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents, Antimicrobial Agents and Chemotherapy42(10):2495-2502 (Oct. 1998).
Del Poeta et al.,In Vitro Antifungal Activities of a Series of Dication-Substituted Cabazoles, Furans, and Benzimidazoles, Antimicrobial Agents and Chemotherapy42(10):2503-2510 (Oct. 1998).
Del Poeta et al.,In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida ssp, J. of Antimicrobial Chemotherapy44:223-228 (1999).
Francesconi et al.,2,4-Diphenyl Furan Diamidines as Novel Anti-Pneumocystis carnii Pneumonia Agents, J. Med. Chem. 42:2260-2265 (1999).
Kumar et al.,Palladium Catalyzed Cross-Coupling Reactions for the Synthesis of 2.5-disubstitutedfurans, Hetercyclic Comm. 5:301-304 (1999).
Lindsay et al.,Activity of Pentamidine and Pentamidine Analogs against Toxoplasma gondii in Cell Cultures, Antimicrobial Agents and Chemotherapy35(9):1914-1916 (Sep. 1991).
Ling et al.,Models for Intramolecular Exchange in Organic π-Conjugated Open-Shell Systems: 3-Nitrenophenyl and 4-Nitrenophenyl Units Connected by 2,5-Furandiyl, 2,5-Thiophenediyl, and 2,5-Pyrrolediyl Nonalternant Exchange Linkers, J. Am. Chem. Soc. 116:8784-8792 (1994).
Shearer et al.,S-2-Naphthylmethyl Thioacetimidate Hydrobromide: A New Odorless Reagent for the Mild Synthesis of Substituted Acetamidines, Tetrahedron Lett. 38:179-182 (1997).
Stephens, et al.,Diguanidino and “Reversed” Diamindino 2,5-Diarylfurans asn Antimicrobial Agents, J. Med. Chem44:1741-1748 (2001).
Thompson et al.,A General Synthesis of 5-Arylnicotinates, J. Org. Chem. 49:5237-5243 (1984).
Boykin David W.
Brun Reto
Ismail Mohamed A.
Tidwell Richard R.
Davis Zinna N.
Georgia State University Research Foundation, Inc.
Jenkins Wilson Taylor & Hunt, P.A.
The University of North Carolina at Chapel Hill
LandOfFree
Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848594